title: Newer antidepressants in pregnancy: prospective outcome of a case series.
abstract: Antidepressant drug choice in pregnancy is a complex problem especially for new drugs. Among 590 cases exposed to drugs during pregnancy who were followed by our center, 21 cases used newer antidepressants, i.e., venlafaxine, mirtazapine, nefazodone. We present the gestational findings and fetal outcomes of these cases. Ten cases had used venlafaxine, one case had used both venlafaxine and mirtazapine, eight had used mirtazapine alone or with some other drugs and two had used nefazodone, in the first trimester. Of the 21 cases, 17 (80.9%) had healthy babies, 3 (14.3%) decided to terminate the pregnancy, and 1 (4.8%) spontaneous abortion was observed in a case exposed to mirtazapine, alprazolam, diazepam and trifluoperazine. All obstetrical findings were normal during the pregnancy of each case. No congenital abnormality and developmental problem was observed in the babies followed up for 12 months. The aim of the present study is to contribute the data to the limited knowledge available in the literature regarding human pregnancy.
authors.affiliation: Department of Family Medicine, School of Medicine, Karadeniz Technical University, TR-61187 Trabzon, Turkey. fyaris@meds.ktu.edu.tr
authors.forename: Fusun
authors.initials: F
authors.lastname: Yaris
authors.forename: Mine
authors.initials: M
authors.lastname: Kadioglu
authors.forename: Murat
authors.initials: M
authors.lastname: Kesim
authors.forename: Cunay
authors.initials: C
authors.lastname: Ulku
authors.forename: Ersin
authors.initials: E
authors.lastname: Yaris
authors.forename: Nuri Ihsan
authors.initials: NI
authors.lastname: Kalyoncu
authors.forename: Mesut
authors.initials: M
authors.lastname: Unsal
mesh_terms: D000014:Abnormalities, Drug-Induced / Q000453:epidemiology / Q000209:etiology; D000328:Adult; D018687:Antidepressive Agents, Second-Generation / Q000009:adverse effects / Q000627:therapeutic use*; D000929:Antidepressive Agents, Tricyclic / Q000009:adverse effects / Q000627:therapeutic use*; D003511:Cyclohexanols / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008803:Mianserin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D000078785:Mirtazapine; D010879:Piperazines; D011247:Pregnancy; D011248:Pregnancy Complications / Q000188:drug therapy; D011256:Pregnancy Outcome; D011446:Prospective Studies; D013723:Teratogens / Q000145:classification / Q000633:toxicity; D014230:Triazoles / Q000009:adverse effects / Q000627:therapeutic use*; D014421:Turkey / Q000453:epidemiology; D000069470:Venlafaxine Hydrochloride
chemical_list: D018687:Antidepressive Agents, Second-Generation; D000929:Antidepressive Agents, Tricyclic; D003511:Cyclohexanols; D010879:Piperazines; D013723:Teratogens; D014230:Triazoles; D008803:Mianserin; C051752:nefazodone; D000069470:Venlafaxine Hydrochloride; D000078785:Mirtazapine